What is Biotricity Inc's earnings per share (EPS)?

Biotricity Inc (BTCY) reported diluted earnings per share of $-0.56 for fiscal year 2025. This represents a 66.6% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Biotricity Inc Financials

BTCY

Source SEC Filings (10-K/10-Q) Updated Dec 31, 2025 Currency USD FYE March

This page shows Biotricity Inc (BTCY) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 11 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI BTCY FY2025 2026-04-22

Gross-margin expansion is steadily shrinking losses, but the business still runs on external financing because liquidity remains tight.

From FY2023 to FY2025, gross margin rose from 56.5% to 76.6% while operating cash burn improved from -$13.5M to -$2.4M; that pairing suggests the core economics and expense base improved together, not just reported losses. But FY2025 cash was only $365K against current liabilities of $20.6M, so the better operating picture has not yet created balance-sheet breathing room.

The business now keeps much more of each sales dollar after production costs, but overhead and financing costs still absorb that gain: FY2025 gross profit was $10.6M, while SG&A plus interest consumed about $14.1M. That makes the remaining profitability gap look more like a cost structure issue than a product-margin issue.

Repeated financing inflows have been covering negative operating cash flow, yet liabilities still climbed from $18.8M in FY2022 to $37.7M in FY2025 as assets fell to $5.6M. That combination means income-statement progress is arriving faster than repair in the company’s funding structure.

Financial Health Signals

Financial Profile 13/100

Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →

Health score ≠ stock price. This rates the quality of Biotricity Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability

Biotricity Inc has an operating margin of -17.8%, meaning the company retains $-18 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is up from -73.2% the prior year.

Growth

Biotricity Inc's revenue grew 14.3% year-over-year to $13.8M, a solid pace of expansion. This earns a growth score of 66/100.

Leverage

Biotricity Inc has elevated debt relative to equity (D/E of -1.18), meaning the company relies heavily on borrowed funds. This high leverage results in a low score of 13/100, reflecting increased financial risk.

Liquidity

Biotricity Inc's current ratio of 0.22 is below the typical benchmark, resulting in a score of 0/100. This tight liquidity could limit financial flexibility if cash inflows slow.

Piotroski F-Score Neutral

5/9

Biotricity Inc passes 5 of 9 financial strength tests. 2 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.

Earnings Quality Low Quality

0.28x

For every $1 of reported earnings, Biotricity Inc generates $0.28 in operating cash flow (-$2.4M OCF vs -$8.4M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Interest Coverage At Risk

-0.8x

Biotricity Inc earns $-0.8 in operating income for every $1 of interest expense (-$2.4M vs $3.3M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$13.8M

YoY+14.3%

5Y CAGR+57.6%

Biotricity Inc generated $13.8M in revenue in fiscal year 2025. This represents an increase of 14.3% from the prior year.

EBITDA

-$2.4M

YoY+72.3%

Biotricity Inc's EBITDA was -$2.4M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 72.3% from the prior year.

Net Income

-$8.4M

YoY+40.3%

Biotricity Inc reported -$8.4M in net income in fiscal year 2025. This represents an increase of 40.3% from the prior year.

EPS (Diluted)

$-0.56

YoY+66.6%

Biotricity Inc earned $-0.56 per diluted share (EPS) in fiscal year 2025. This represents an increase of 66.6% from the prior year.

Cash & Balance Sheet

Free Cash Flow

N/A

Cash & Debt

$365K

YoY-53.5%

5Y CAGR-17.4%

10Y CAGR-2.0%

Biotricity Inc held $365K in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

25M

YoY+167.3%

Biotricity Inc had 25M shares outstanding in fiscal year 2025. This represents an increase of 167.3% from the prior year.

Margins & Returns

Gross Margin

76.6%

YoY+7.3pp

5Y CAGR+42.4pp

Biotricity Inc's gross margin was 76.6% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 7.3 percentage points from the prior year.

Operating Margin

-17.8%

YoY+55.4pp

Biotricity Inc's operating margin was -17.8% in fiscal year 2025, reflecting core business profitability. This is up 55.4 percentage points from the prior year.

Net Margin

-61.1%

YoY+55.8pp

Biotricity Inc's net profit margin was -61.1% in fiscal year 2025, showing the share of revenue converted to profit. This is up 55.8 percentage points from the prior year.

Return on Equity

N/A

Capital Allocation

R&D Spending

$2.2M

YoY-16.2%

5Y CAGR+9.6%

10Y CAGR+10.0%

Biotricity Inc invested $2.2M in research and development in fiscal year 2025. This represents a decrease of 16.2% from the prior year.

Share Buybacks

N/A

Capital Expenditures

N/A

BTCY Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$13.8M+14.3%	$12.1M+25.2%	$9.6M+26.0%	$7.7M+126.0%	$3.4M+138.7%	$1.4M
Cost of Revenue	$3.2M-13.0%	$3.7M-11.7%	$4.2M+36.3%	$3.1M+45.8%	$2.1M+126.6%	$932K
Gross Profit	$10.6M+26.4%	$8.4M+53.6%	$5.4M+19.1%	$4.6M+259.1%	$1.3M+162.0%	$486K
R&D Expenses	$2.2M-16.2%	$2.6M-20.4%	$3.2M+17.7%	$2.7M+33.3%	$2.1M+51.0%	$1.4M
SG&A Expenses	$10.9M-25.7%	$14.6M-17.1%	$17.6M-5.1%	$18.6M+47.7%	$12.6M	N/A
Operating Income	-$2.4M+72.3%	-$8.8M+42.7%	-$15.4M+7.9%	-$16.7M	N/A	N/A
Interest Expense	$3.3M+8.1%	$3.0M+64.1%	$1.8M+43.3%	$1.3M+745.6%	$152K	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$8.4M+40.3%	-$14.1M+24.5%	-$18.7M+35.9%	-$29.1M-88.0%	-$15.5M	N/A
EPS (Diluted)	$-0.56+66.6%	$-1.66+26.4%	$-2.26	N/A	N/A	N/A

Metric	Q3'26	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24
Revenue	$4.0M+2.6%	$3.9M+0.3%	$3.9M+4.6%	$3.7M+2.3%	$3.6M+10.8%	$3.3M+2.0%	$3.2M+0.7%	$3.2M
Cost of Revenue	$736K+4.6%	$704K-7.0%	$757K+4.5%	$724K-15.3%	$855K+5.9%	$808K-3.7%	$839K-7.4%	$906K
Gross Profit	$3.3M+2.2%	$3.2M+2.1%	$3.1M+4.7%	$3.0M+7.8%	$2.8M+12.4%	$2.5M+4.1%	$2.4M+4.0%	$2.3M
R&D Expenses	$624K+3.4%	$603K-13.4%	$696K+21.6%	$573K+3.9%	$551K+6.4%	$518K+0.8%	$514K-27.4%	$708K
SG&A Expenses	$2.2M-5.1%	$2.3M+7.8%	$2.1M-34.4%	$3.3M+36.9%	$2.4M+5.9%	$2.2M-24.2%	$3.0M-35.6%	$4.6M
Operating Income	$441K+61.0%	$274K-2.9%	$282K+133.0%	-$855K-406.2%	-$169K+45.1%	-$308K+72.5%	-$1.1M+63.3%	-$3.0M
Interest Expense	$810K-5.8%	$860K+1.2%	$850K-4.7%	$892K+5.0%	$850K+13.0%	$752K-2.2%	$769K-5.7%	$815K
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$717K-3.8%	-$691K-2.8%	-$672K+65.3%	-$1.9M-57.5%	-$1.2M+21.3%	-$1.6M+57.7%	-$3.7M+11.7%	-$4.2M
EPS (Diluted)	$-0.04-44.8%	$-0.030.0%	$-0.03	N/A	$-0.05+26.0%	$-0.07+85.1%	$-0.49	N/A

BTCY Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$5.6M-5.1%	$5.9M-8.7%	$6.5M-61.0%	$16.7M+275.8%	$4.4M+121.4%	$2.0M
Current Assets	$4.6M+3.8%	$4.5M-5.3%	$4.7M-69.2%	$15.3M+254.6%	$4.3M+160.5%	$1.7M
Cash & Equivalents	$365K-53.5%	$786K+37.8%	$570K-95.3%	$12.1M+448.1%	$2.2M+131.8%	$950K
Inventory	$1.6M-17.2%	$1.9M-19.6%	$2.3M+177.2%	$843K+209.3%	$272K+217.9%	$86K
Accounts Receivable	$1.7M+12.9%	$1.5M+20.0%	$1.2M-39.0%	$2.0M+31.9%	$1.5M+212.8%	$486K
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$37.7M+0.7%	$37.4M+41.9%	$26.4M+40.0%	$18.8M+67.0%	$11.3M+125.2%	$5.0M
Current Liabilities	$20.6M-9.1%	$22.7M+103.4%	$11.2M+129.3%	$4.9M-53.6%	$10.5M+175.8%	$3.8M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	-$32.0M-1.7%	-$31.5M-58.6%	-$19.8M-825.3%	-$2.1M+68.6%	-$6.8M-127.7%	-$3.0M
Retained Earnings	-$139.4M-9.4%	-$127.5M-13.3%	-$112.6M-21.0%	-$93.0M-48.1%	-$62.8M-35.5%	-$46.4M

Metric	Q3'26	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24
Total Assets	$5.7M-10.1%	$6.3M+4.7%	$6.0M+7.0%	$5.6M-5.8%	$6.0M+13.1%	$5.3M-2.4%	$5.4M-8.8%	$5.9M
Current Assets	$5.0M-10.0%	$5.5M+7.6%	$5.1M+10.9%	$4.6M-4.6%	$4.9M+19.6%	$4.1M-0.7%	$4.1M-8.4%	$4.5M
Cash & Equivalents	$256K-16.9%	$308K-21.2%	$391K+7.2%	$365K-28.3%	$510K+194.1%	$173K+72.0%	$101K-87.2%	$786K
Inventory	$2.0M-12.5%	$2.3M+26.5%	$1.8M+14.7%	$1.6M-0.9%	$1.6M-13.6%	$1.8M-5.0%	$1.9M+1.8%	$1.9M
Accounts Receivable	$1.6M-24.8%	$2.1M+12.8%	$1.9M+12.2%	$1.7M+34.2%	$1.2M-17.6%	$1.5M-1.2%	$1.5M+3.4%	$1.5M
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$39.9M+0.5%	$39.7M+2.3%	$38.8M+3.1%	$37.7M-0.7%	$37.9M+4.0%	$36.5M+3.6%	$35.2M-5.9%	$37.4M
Current Liabilities	$23.8M+0.8%	$23.6M+8.3%	$21.8M+5.7%	$20.6M-2.4%	$21.1M-1.6%	$21.5M+4.4%	$20.6M-9.3%	$22.7M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	-$34.2M-2.5%	-$33.4M-1.9%	-$32.8M-2.5%	-$32.0M-0.2%	-$31.9M-2.5%	-$31.2M-4.7%	-$29.8M+5.4%	-$31.5M
Retained Earnings	-$142.1M-0.8%	-$141.0M-0.6%	-$140.2M-0.5%	-$139.4M-1.5%	-$137.4M+1.5%	-$139.4M0.0%	-$139.4M-9.4%	-$127.5M

BTCY Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$2.4M+64.4%	-$6.7M+50.6%	-$13.5M+10.7%	-$15.2M-36.8%	-$11.1M-40.9%	-$7.9M
Capital Expenditures	N/A	N/A	N/A	$30K	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	-$15.2M	N/A	N/A
Investing Cash Flow	N/A	N/A	N/A	-$30K	N/A	N/A
Financing Cash Flow	$1.9M-71.4%	$6.7M+236.8%	$2.0M-92.0%	$25.2M+106.2%	$12.2M+37.4%	$8.9M
Dividends Paid	N/A	N/A	N/A	N/A	$603K+235.0%	$180K
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q3'26	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24
Operating Cash Flow	-$740K-278.1%	$416K+211.3%	-$373K+6.8%	-$401K-355.0%	-$88K+77.8%	-$397K+73.4%	-$1.5M-28.2%	-$1.2M
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Financing Cash Flow	$721K+242.1%	-$508K-216.5%	$436K+164.0%	$165K-61.2%	$425K-9.8%	$471K-45.7%	$868K-51.5%	$1.8M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

BTCY Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	76.6%+7.3pp	69.3%+12.8pp	56.5%-3.3pp	59.7%+22.1pp	37.6%+3.3pp	34.3%
Operating Margin	-17.8%+55.4pp	-73.2%+86.7pp	-159.9%+58.9pp	-218.8%	N/A	N/A
Net Margin	-61.1%+55.8pp	-116.8%+76.7pp	-193.6%+187.2pp	-380.8%+76.9pp	-457.7%	N/A
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	-149.3%+87.9pp	-237.2%+49.4pp	-286.6%-111.9pp	-174.7%+174.4pp	-349.1%	N/A
Current Ratio	0.22+0.0	0.20-0.2	0.42-2.7	3.15+2.7	0.41-0.0	0.44
Debt-to-Equity	-1.18+0.0	-1.19+0.1	-1.33+7.4	-8.78-7.1	-1.65+0.0	-1.67
FCF Margin	N/A	N/A	N/A	-198.6%	N/A	N/A

Metric	Q3'26	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24
Gross Margin	81.5%-0.3pp	81.9%+1.4pp	80.5%+0.0pp	80.4%+4.1pp	76.4%+1.1pp	75.3%+1.5pp	73.8%+2.3pp	71.5%
Operating Margin	11.1%+4.0pp	7.0%-0.2pp	7.3%+30.4pp	-23.1%-18.4pp	-4.7%+4.8pp	-9.4%+25.5pp	-34.9%+60.9pp	-95.8%
Net Margin	-18.0%-0.2pp	-17.8%-0.4pp	-17.3%+34.9pp	-52.3%-18.3pp	-34.0%+13.9pp	-47.8%+67.6pp	-115.4%+16.2pp	-131.6%
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	-12.6%-1.7pp	-10.9%+0.2pp	-11.1%+23.2pp	-34.3%-13.8pp	-20.5%+9.0pp	-29.5%+38.6pp	-68.2%+2.2pp	-70.4%
Current Ratio	0.21-0.0	0.230.0	0.24+0.0	0.220.0	0.23+0.0	0.190.0	0.200.0	0.20
Debt-to-Equity	-1.17+0.0	-1.190.0	-1.180.0	-1.18+0.0	-1.19-0.0	-1.17+0.0	-1.180.0	-1.19
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Note: Shareholder equity is negative (-$32.0M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Note: The current ratio is below 1.0 (0.22), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.

Similar Companies

Guided Thera GTHP

$17.4M

CS Diagnostics CSDX

$15.5M

Perimeter Medical Imaging Ai Inc PYNKF

$37.7M

PharmChem, Inc. PCHM

$17.3M

Petvivo Hldgs Inc PETV

$28.8M

Frequently Asked Questions

What is Biotricity Inc's annual revenue?

Biotricity Inc (BTCY) reported $13.8M in total revenue for fiscal year 2025. This represents a 14.3% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Biotricity Inc's revenue growing?

Biotricity Inc (BTCY) revenue grew by 14.3% year-over-year, from $12.1M to $13.8M in fiscal year 2025.

Is Biotricity Inc profitable?

No, Biotricity Inc (BTCY) reported a net income of -$8.4M in fiscal year 2025, with a net profit margin of -61.1%.

What is Biotricity Inc's EBITDA?

Biotricity Inc (BTCY) had EBITDA of -$2.4M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Biotricity Inc's gross margin?

Biotricity Inc (BTCY) had a gross margin of 76.6% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Biotricity Inc's operating margin?

Biotricity Inc (BTCY) had an operating margin of -17.8% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Biotricity Inc's net profit margin?

Biotricity Inc (BTCY) had a net profit margin of -61.1% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Biotricity Inc's operating cash flow?

Biotricity Inc (BTCY) generated -$2.4M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Biotricity Inc's total assets?

Biotricity Inc (BTCY) had $5.6M in total assets as of fiscal year 2025, including both current and long-term assets.

How much does Biotricity Inc spend on research and development?

Biotricity Inc (BTCY) invested $2.2M in research and development during fiscal year 2025.

How many shares does Biotricity Inc have outstanding?

Biotricity Inc (BTCY) had 25M shares outstanding as of fiscal year 2025.

What is Biotricity Inc's current ratio?

Biotricity Inc (BTCY) had a current ratio of 0.22 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.

What is Biotricity Inc's debt-to-equity ratio?

Biotricity Inc (BTCY) had a debt-to-equity ratio of -1.18 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Biotricity Inc's return on assets (ROA)?

Biotricity Inc (BTCY) had a return on assets of -149.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Biotricity Inc's cash runway?

Based on fiscal year 2025 data, Biotricity Inc (BTCY) had $365K in cash against an annual operating cash burn of $2.4M. This gives an estimated cash runway of approximately 2 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

Why is Biotricity Inc's debt-to-equity ratio negative or unusual?

Biotricity Inc (BTCY) has negative shareholder equity of -$32.0M as of fiscal year 2025, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

What is Biotricity Inc's Piotroski F-Score?

Biotricity Inc (BTCY) has a Piotroski F-Score of 5 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Biotricity Inc's earnings high quality?

Biotricity Inc (BTCY) has an earnings quality ratio of 0.28x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Biotricity Inc cover its interest payments?

Biotricity Inc (BTCY) has an interest coverage ratio of -0.8x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Biotricity Inc?

Biotricity Inc (BTCY) scores 13 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.